Management of Acute Hepatitis C

Clinics in Liver Disease

Volumn 14, Issue 1, 2010, Pages 169-176

  Maheshwari, Anurag ^a   Thuluvath, Paul J ^a,b  

^a MERCY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis C; Interferon; Intravenous drug use; Sustained virological response

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; IMMUNOGLOBULIN M ANTIBODY; INTERFERON; LIVER ENZYME; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ACUTE HEPATITIS; AGE; ALGORITHM; ANTIBODY DETECTION; ANTIBODY RESPONSE; CHRONIC HEPATITIS; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENDER; GENOTYPE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOLYTIC ANEMIA; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MENTAL DISEASE; MIXED INFECTION; MONOTHERAPY; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; RISK REDUCTION; SEROCONVERSION; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ACUTE DISEASE; ALGORITHMS; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HEPATITIS A ANTIBODIES; HEPATITIS C; HUMANS; RENAL DIALYSIS; RNA, VIRAL;

EID: 74549181323     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.11.007     Document Type: Review

References (29)

1. WHO. Hepatitis C - Global prevalence (update). Wkly Epidemiol Rec 49 (1999) 421-428
2. Wiegand J., Deterding K., Cornberg M., et al. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother 62 (2008) 860-865
3. Farci P., Alter H.J., Wong D., et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 325 (1991) 98-104
4. Quiroga J.A., Campillo M.L., Catillo I., et al. IgM antibody to hepatitis C virus in acute and chronic hepatitis C. Hepatology 14 (1991) 38-43
5. Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 50 RR-11 (2001) 1-42
6. Alberti A., Boccato S., Vario A., et al. Therapy of acute hepatitis C. Hepatology 36 (2002) S195-S200
7. Licata A., Di Bona D., Schepis F., et al. When and how to treat acute hepatitis C?. J Hepatol 39 (2003) 1056-1062
8. Hofer H., Watkins-Riedel T., Janata O., et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 37 (2003) 60-64
9. Gerlach J.T., Diepolder H.M., Zachoval R., et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125 (2003) 80-88
10. Kamal S.M., Fouly A.E., Kamel R.R., et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 130 (2006) 632-638
11. Jaeckel E., Cornberg M., Wedemeyer H., et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345 (2001) 1452-1457
12. Santantonio T., Fasano M., Sinisi E., et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 42 (2005) 329-333
13. Deterding K., Grüner N., Wiegand J., et al. Early versus delayed treatment of acute Hepatitis C: the German HEP-NET acute HCV-III study - A randomized controlled trial. J Hepatol 50 (2009) S380
14. Nomura H., Sou S., Tanimoto H., et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 39 (2004) 1213-1219
15. Wiegand J., Buggisch P., Boecher W., et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43 (2006) 250-256
16. Broers B., Helbling B., Francois A., et al. Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 42 (2005) 323-328
17. De Rosa F.G., Bargiacchi O., Audagnotto S., et al. Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users. Clin Infect Dis 45 (2007) 583-588
18. Calleri G., Cariti G., Gaiottino F., et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat 14 (2007) 116-121
19. De Rosa F.G., Bargiacchi O., Audagnotto S., et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. J Antimicrob Chemother 57 (2006) 360-363
20. Kamal S.M., Moustafa K.N., Chen J., et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 43 (2006) 923-931
21. Corey K.E., Ross A.S., Wurcel A., et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol 4 (2006) 1278-1282
22. Gilleece Y.C., Browne R.E., Asboe D., et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 40 (2005) 41-46
23. Dominguez S., Ghosn J., Valantin M.A., et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 20 (2006) 1157-1161
24. Vogel M., Nattermann J., Baumgarten A., et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther 11 (2006) 1097-1101
25. Soriano V., Puoti M., Sulkowski M., et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 21 (2007) 1073-1089
26. Rocha C.M., Perez R.M., Narciso J.L., et al. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance. Eur J Gastroenterol Hepatol 19 (2007) 119-123
27. Al-Harbi A.S., Malik G.H., Subaity Y., et al. Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. Saudi J Kidney Dis Transpl 16 (2005) 293-297
28. Griveas I., Germanidis G., Visvardis G., et al. Acute hepatitis C in patients receiving hemodialysis. Ren Fail 29 6 (2007) 731-736
29. Gürsoy M., Gür G., Arslan H., et al. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 8 (2001) 70-77